TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer) [TIGIT/3017]



TIGIT is a checkpoint inhibitor which binds with high affinity to the poliovirus receptor (PVR), causing increased IL10 secretion, decreased IL12B secretion. TIGIT binding to PVR also causes the suppression of T cell activation by promoting the generation of mature immuno-regulatory dendritic cells. It is expressed at low levels on natural killer (NK) cells, as well as peripheral memory and regulatory CD4+ T cells. At the protein level, it is upregulated following the activation of these cells. Functionally, TIGIT is similar to CTLA4. The ligands for TIGIT include CD155 (signal abrogation) and CD226 (signal stimulation). It has been demonstrated to be upregulated on T cells in many cancers and is an immuno-oncology target for therapy.

Product Properties & Targets

Species Reactivity
Cellular Localization
Light Chain
Gene Name
Positive Control
Molt-4, Prostate or Colon Carcinoma.
Recombinant fragment (around aa 22-141) of human TIGIT protein (exact sequence is proprietary)
Alternate Names
Homeobox protein Nkx-3.1, Homeobox protein NK-3 homolog A, T-cell immunoreceptor with Ig and ITIM domains; V-set and immunoglobulin domain containing 9 (VSIG9); V-set and transmembrane domain containing 3 (VSTM3); Washington University cell adhesion molecule (WUCAM)

Database Links

Entrez Gene ID

Additional Information

Human Gene Symbol
Chromosome Location
Mol. Weight of Antigen


  • Transcription factor, which binds preferentially the consensus sequence 5'-TAAGT[AG]-3' and can behave as a transcriptional repressor. Plays an important role in normal prostate development, regulating proliferation of glandular epithelium and in the formation of ducts in prostate. Acts as a tumor suppressor controlling prostate carcinogenesis, as shown by the ability to inhibit proliferation and invasion activities of PC-3 prostate cancer cells.

Known Applications & Suggested Dilutions

  • ELISA (For coating, order antibody without BSA)
  • Flow Cytometry (1-2ug/million cells)
  • ,Immunohistochemistry (Formalin-fixed) (1-2ug/ml for 30 minutes at RT),(Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95&degC followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined.

Key References

  • Johnston et al., The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function, Cancer Cell (2014)
  • Dougall WC, et al. TIGIT and CD96: New checkpoint receptor targets for cancer immunotherapy. Immunol Rev. 2017;276: 112-120

Storage & Stability

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.


This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.


There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.


There are no reviews yet.

Be the first to review “TIGIT / VSTM3 / VSIG9 (Immune Checkpoint for Cancer)”

Your email address will not be published. Required fields are marked *

Recombinant mouse monoclonal antibodies and recombinant rabbit monoclonals to support your research

Shop Primary Antibodies